Former Cigna VP: Health insurance industry has erect barriers making it more difficult to seek care
Wendell Potter, Center for Health and Democracy president and former Cigna vice president, joins 'Squawk Box' to discuss public anger at the health care industry, problems with health insurance, and more.
Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
Cigna (CI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Barclays fact-checked Trump comments on pharmacy benefit managers
Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support for legislation. Trump said he planned to "knock out the middleman" which is the latest in a string of negative headlines that drove PBM-owned stocks Cigna (CI), CVS Health (CVS) and UnitedHealth (UNH) lower, the analyst told investors yesterday in a research note. The firm believes PBMs "are the only market-based check on drug pricing that exists today," and eliminating the "middleman" would effectively put the government in charge of negotiating drug prices for both private and government-sponsored health plans. Trump, said, "The horrible middleman that makes more money frankly than the drug companies and they don't do anything except they're a middleman, we're going to knock out the middleman." Barclays fact-checked this and notes the average EBIT margins of the top six U.S. pharmaceutical companies is 37%, nearly 8-10 times PBM margins, which are closer to 3%-5%. Four of the six largest drug manufacturers, Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), Pfizer (PFE) are estimated to earn more operating profits this year than the "Big Three" PBMs combined, according to Barclays. CVS Health -2.11 (-4.53%) Cigna -8.06 (-2.95%) UnitedHealth -19.06 (-3.83%) Johnson & Johnson +1.65 (+1.15%) AbbVie +2.88 (+1.68%) Merck +0.07 (+0.07%) Pfizer +1.115 (+4.41%)
Cigna: I'm Loading Up On This Dividend Growth Stock Now
Cigna's strong fundamentals, including consistent revenue and EPS growth, a solid balance sheet, and undervalued stock price, support a buy rating. The company's Q3 results showed a 29.9% revenue increase and a 10.9% rise in non-GAAP EPS, driven by customer growth and price hikes. Cigna's dividend yield and growth potential are robust, with a low payout ratio and projected double-digit annual EPS growth supporting future dividend increases.
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its pricier drugs, The Wall Street Journal reported on Friday.
Here's Why Cigna (CI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna's stock leads selloff among drug middlemen on breakup fears — but this analyst says it's not a real risk
One influential healthcare analyst says the chances of such a bill passing are less than 5%.
Health care stocks fall as lawmakers, patients push for changes to their business models
Shares of major healthcare companies fell nearly 5% on Wednesday on concerns related to potential changes to their complex business models. That includes UnitedHealth Group, Cigna and CVS Health, which operate three of the nation's largest private health insurers and drug supply chain middlemen called pharmacy benefit managers.
Here's Why Retaining Cigna Stock is a Smart Move for Investors Now
CI is well-poised for growth on the back of strong contributions from the Evernorth and Cigna Healthcare units. A strong financial position enables it to undertake business investments.
Here's Why Cigna (CI) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cigna Ends Humana Merger Speculation: CI Jumps 7.3% While HUM Slips
CI reaffirms its 2024 outlook, projecting full-year adjusted EPS to be a minimum of $28.40.
3-Stock Lunch: Cigna, Coinbase, & Draft Kings
Victoria Greene, G Squared Private Wealth CIO, joins CNBC's 'Power Lunch' to discuss three stocks: Cigna, Coinbase, and Draft Kings.
